Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech Thrashed the Market on Thursday

By Eric Volkman – Sep 23, 2021 at 4:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With its latest ruling on the biotech's coronavirus vaccine, the FDA boosts the investment case for the stock.

What happened

Top coronavirus stock BioNTech (BNTX -0.88%) was also tops with investors on Thursday. The Germany-based biotech's shares trounced the S&P 500 by closing the day more than 4% higher, thanks to some positive -- if expected -- news on the regulatory front.

So what

Comirnaty, the coronavirus vaccine developed by BioNTech in partnership with U.S. pharmaceutical sector giant Pfizer (PFE 0.74%), was granted Emergency Use Authorization as a booster by the Food and Drug Administration Wednesday night.

Person receiving an injection.

Image source: Getty Images.

The vaccine is currently the only one fully approved by the regulator to prevent COVID-19. Two other vaccines, from biotech Moderna and Johnson & Johnson's Janssen, are in circulation under EUAs.

The Comirnaty booster's EUA covers people 65 years of age and older. It also applies to individuals age 18 to 64 with either high risk of severe COVID-19, or, as the FDA wrote in an official press release on the matter, "whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications" from the disease.

In a statement, BioNTech CEO Uğur Şahin said the company would "continue to monitor new SARS-CoV-2 strains, to be prepared for potential emerging escape variants."

Now what

BioNTech and Pfizer added that they are continuing to supply the vaccine under their current arrangement with the U.S. government, which runs through next April. According to the companies, this arrangement includes "sufficient volume for boosters."

The booster shots are likely not going to affect the financial projections for either company; however, the approval will bolster Comirnaty's status as the leading coronavirus vaccine administered in this country. 

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson and Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
BNTX
$154.85 (-0.88%) $-1.38
Pfizer Stock Quote
Pfizer
PFE
$49.21 (0.74%) $0.36
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$177.24 (0.13%) $0.23
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$176.40 (-0.23%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
360%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.